Abstract

Background: GISTs are the most common mesenchymal tumors of gastrointestinal tract (GI) and account for 0,1% to 0,3% of all GI tumors. Their biological behavior is difficult to predict, ranging from clinically benign to malignant. Tumor size, mitotic rate, and anatomic location correlate with potential malignancy and recurrence rate. Treatment with tyrosine kinase inhibitors has revolutionized therapy for gists, but complete resection remains the treatment of choice. Our aim is to analyze the outcome of 52 patients with gastrointestinal stromal tumor (GIST) who were treated at a single

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.